NCT05368103Phase 2Completed
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
In the register
The register attaches this trial to Daxdilimab (Amgen), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Amgen
- Participants (registry)
- 30
- Start
- April 2022
- Primary completion
- August 2023
- Study completion
- January 2024
- Last registry update
- January 2025
- Countries
- United States, Canada
Conditions studied: Alopecia Areata
Interventions: Daxdilimab, HZN-7734
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.